Gastro-esophageal Reflux Disease (GERD) Withdrawn Phase 3 Trials for Pantoprazole (DB00213)

Also known as: Reflux Disease, Gastro-Esophageal / Oesophageal Reflux / Gastroesophageal Refluxdisease / Gastrooesophageal reflux disease / Gastro-esophageal Reflux Disease / GERD / Esophageal Reflux / Gastroesophageal Reflux Disease (GERD) / Gastro Oesophageal Reflux Disease / Gastro-esophageal Reflux Diseases / GERD (Gastroesophageal Reflux Disease) / Gastro-Oesophageal Reflux Disease / GERD - Gastro-Esophageal Reflux Disease / GERD Gastroesophageal Reflux Disease / Gastroesophageal Reflux Disease / Gastro Esophageal Reflux Disease / Gastrooesophageal reflux / Gastroesophageal reflux / Acid reflux (finding) / GORD / Gastro-esophageal reflux disease without esophagitis / Gastroesophageal reflux disease (disorder) / Esophageal reflux finding (finding)

IndicationStatusPhase
DBCOND0077290 (Gastro-esophageal Reflux Disease (GERD))Withdrawn3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01710462Clinical Study, Multicenter, Randomized With 2 Arms of Pantoprazole + Domperidone and Pantoprazole Isolated at the Gastroesophageal Reflux DiseaseTreatment